Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license
Five separate metabolomics studies used mass spectrometry or NMR to measure hundreds of small molecules in blood and urine, and repeatedly converged on the same handful of metabolism genes.
Blood metabolite levels refers to the concentrations of small molecules — amino acids, lipids, sugars, and other metabolic byproducts — circulating in blood or excreted in urine, measured directly with mass spectrometry or NMR spectroscopy rather than the handful of standard clinical labs (like glucose or cholesterol) ordered in routine care. This page is about that broad research measurement, distinct from this site's separate Metabolic Syndrome page, which covers the specific clinical risk factors used to diagnose that syndrome.
Suhre et al. 2011 ran a landmark non-targeted metabolomics GWAS and found 37 genetic loci associated with blood metabolite concentrations, 25 of them with unusually large effect sizes — some alleles shifted a metabolite's level by 10-60% per copy, far larger than typical GWAS effects on disease risk. Sixteen of this page's variants trace directly to that paper, including rs662138 in SLC22A1, a liver drug transporter, and rs612169 in ABO, the same blood-type gene with effects across many unrelated traits on this site.
Four smaller, more targeted studies independently converged on several of the same genes. Illig et al. 2010, in 1,809 people (replicated in 422 more), named eight loci directly, including FADS1, ACADS, ACADM, and ACADL — all fatty-acid metabolism genes — matching five of this page's own variants. Hong et al. 2013, in 402 people (replicated in 489 more), separately named FADS1 and ACADL among its seven loci — the same two genes Illig's study had already implicated. Nicholson et al. 2011 found that rs9309473, in NAT8, sits in a haplotype block bearing the genetic signature of recent positive selection in Europeans. And Xie et al. 2013, in 1,004 people (replicated in 342 more), traced variants in the glycine and betaine metabolism pathway; this page's rs17823642 sits in BHMT2, in the same gene cluster as that paper's own BHMT finding, though not an exact match to its named gene.
Taken together, the repeated independent discovery of the same fatty-acid and one-carbon metabolism genes — FADS1, the ACAD family, and the betaine pathway — across five separate cohorts is a stronger form of evidence than any single study alone.
2026-05-02 · Population-based genome-wide association study of plasma complex lipid species. Nature Communications. 2026. DOI:10.1038/s41467-026-72542-1
Standard cholesterol/triglyceride panels measure only a handful of broad lipid categories, but the human lipidome actually contains hundreds of distinct molecular species whose individual genetic architecture was mostly unknown. This study ran GWAS on 970 individual lipid species and 267 fatty-acid composite measures using the Rhineland Study (n=6,096), validating findings in two independent cohorts (FinnGen, EPIC-Potsdam). Of 217 lead genomic loci found, 136 were novel, including FDFT1. Using Mendelian randomization and gene-expression data, the study identified 43 likely causal gene-to-lipid-species relationships, including FDFT1 driving a specific diacylglycerol species (16:0/18:0). This kind of granular lipid-species genetics matters because different lipid species within the same broad category (e.g., different triglyceride or diacylglycerol subtypes) can have very different disease relevance, information a standard lipid panel collapses into one number. This site's blood metabolite levels page carries 26 variants; FDFT1 and the newly identified loci are not currently among them.
These metabolite panels are research tools, not standard clinical tests, and none of the variants here changes how any disease is diagnosed or treated. Suhre et al. 2011 specifically noted these findings offer functional insight into previously reported disease associations — they do not replace clinical testing.
Unlike a routine glucose or cholesterol test, the metabolomics platforms behind this page's findings measure hundreds of metabolites at once using mass spectrometry or NMR — research infrastructure, not something available through ordinary clinical labs. For clinical risk factors specifically, see this site's Metabolic Syndrome page.
The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 28 of 57 linked studies with a resolved discovery ancestry.
Databases, guidelines and references
Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license
Blood Metabolite Levels. MyGeneLog™. https://www.mygenelog.com/conditions/blood-metabolite-levels
Blood metabolite levels are the concentrations of small molecules — amino acids, lipids, sugars, and other metabolic byproducts — circulating in blood or urine, measured with mass spectrometry or NMR rather than standard clinical labs.
Five separate studies, the largest by Suhre et al. 2011 finding 37 loci, repeatedly converged on the same genes — particularly FADS1 and the ACAD family of fatty-acid metabolism genes — across independent cohorts.
No. These metabolomics platforms measure hundreds of metabolites at once using mass spectrometry or NMR — research tools, not the handful of standard tests (like glucose or cholesterol) ordered in routine clinical care.
No individual variant does. These are population-level statistical associations with metabolite concentrations, and Xie et al. 2013 specifically found no robust link between their glycine-pathway variants and diabetes itself.
Free to reuse, non-commercially. This page's text is original writing from freely-available research, licensed CC BY-NC 4.0 — share and adapt it with attribution to MyGeneLog™; commercial use is licensed. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.